Company Overview of Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
2505 Meridian Parkway
Durham, NC 27713
Founded in 2000
Key Executives for Chimerix, Inc.
Chief Executive Officer
Total Annual Compensation: $340.0K
Chief Financial Officer
Total Annual Compensation: $275.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.
Chimerix, Inc. Key Developments
Chimerix, Inc. Announces New Product Candidate, CMX16669 to Development Pipeline
Oct 16 14
Chimerix, Inc. provided an update on the company's R&D programs, including the addition of a potential new product candidate, CMX16669, to its development pipeline. The company has discovered, developed and selected a novel clinical candidate, CMX16669, for BK virus and cytomegalovirus (CMV). This new product candidate has demonstrated potent in vitro activity against CMV and BK virus, with a promising safety profile in vitro and in pilot toxicity studies in animals. The modified lipid tail may enable very low oral doses, based on initial animal studies. The company plans to initiate clinical trials in 2015.
Chimerix, Inc. - Special Call
Oct 13 14
To discuss the company's R&D update and annual Meeting
Chimerix, Inc. Announces Preliminary Data for its Investigational Antiviral Brincidofovir
Oct 8 14
Chimerix, Inc. announced preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. The preliminary survival analysis data, based on 48 evaluable patients from the ongoing AdVise Trial, showed a mortality rate of 35% compared with the historic rates of up to 80% mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, an infection that can progress rapidly in patients with a weakened immune system due to disease or medications. Chimerix initiated AdVise in March 2014 based on potency observed in vitro and on clinical data from a Phase 2 trial and a large expanded access trial which showed the potential for improved clinical outcomes. The trial is enrolling pediatric and adult patients with adenovirus infection who receive brincidofovir twice weekly for twelve weeks. Baseline information and at least two months of follow up are available for 26 subjects. Of those 26 patients, 23 had measurable viral loads at study entry, and three patients had no virus detectable in the blood but had diagnosed adenovirus infection. Fourteen of the 23 patients with viremia at study entry achieved undetectable viral loads during treatment. Twelve of the 26 patients died. Over half of the subjects were hematopoeitic cell transplant (HCT) recipients with disseminated disease, but solid organ transplant recipients and patients undergoing chemotherapy were also enrolled. Over one-third of the subjects (10 of 26) had a second active infection with another DNA virus in addition to adenovirus, including BK virus (27%), cytomegalovirus (19%) and Epstein Barr virus (8%). The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events. Of the six subjects who enrolled in the study with adenovirus-related diarrhea, three reported improvement of symptoms and three remained stable.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|